According to a DARA regulatory filing, Uman is responsible for formulation, analytical and manufacturing work on the drug. Uman must also make the abbreviated new drug application for U.S. marketing ...
(), a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products, announced today the appointment of Timothy J. Heady to the ...
(Nasdaq:DARA) announced today that it has entered into an exclusive distribution agreement with for the sale and distribution of (tamoxifen citrate, oral solution) in the Commonwealth of Puerto Rico.
RALEIGH, NC, Jun 16, 2014 (Marketwired via COMTEX) -- DARA BioSciences, Inc. DARA +23.21% , an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals ...
RALEIGH, N.C. and WEST HAVEN, Conn., Oct. 17 -- DARA BioSciences, Inc. and Bayer Pharmaceuticals Corporation (BPC), a U.S. subsidiary of Bayer HealthCare AG signed a license agreement granting DARA ...
Drug development company DARA BioSciences is updating its plans to raise up to $30 million through a stock sale. Raleigh, North Carolina-based DARA (NASDAQ:DARA) has filed a new shelf registration ...
Christopher G. Clement is President and Chief Executive Officer of DARA BioSciences, Inc. Mr. Clement was the Co-Founder of Oncogenerix, Inc., a privately held specialty biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results